Prospects for developing an effective particle-mediated DNA vaccine against influenza

Expert Review of Vaccines

Volumn 8, Issue 9, 2009, Pages 1205-1220

  Yager, Eric J ^a   Dean, Hansi J ^b   Fuller, Deborah Heydenburg ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Aging; Antibody; DNA; Influenza; Mucosal immunity; T cell; Vaccine

Indexed keywords

DNA VACCINE; GOLD NANOPARTICLE; IMIDAZOQUINOLINE DERIVATIVE; INFLUENZA VACCINE; INTERLEUKIN 23; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33R; PLASMID DNA; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ELDERLY CARE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SKIN MANIFESTATION; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

ANIMALS; BIOLISTICS; BIOMEDICAL RESEARCH; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, DNA;

EID: 70249111216     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.82     Document Type: Review

References (138)

1. Guan Y, Shortridge KF, Krauss S et al. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. J. Virol. 74(20), 9372-9380 (2000).
2. CDC. Swine influenza A (H1N1) infection in two children - southern California, March-April 2009. MMWR Morb. Mortal. Wkly Rep. 58(15), 400-402 (2009).
3. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009).
4. Schoch-Spana M. Implications of pandemic influenza for bioterrorism response. Clin. Infect. Dis. 31(6), 1409-1413 (2000).
5. Glezen WP. Emerging infections: pandemic influenza. Epidemiol. Rev. 18(1), 64-76 (1996).
6. Gross PA. Preparing for the next influenza pandemic: a reemerging infection. Ann. Intern. Med. 124(7), 682-685 (1996).
7. Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J. Infect. Dis. 176(Suppl. 1), S4-S7 (1997).
8. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136(2), 168-175 (2000).
9. Laver WG, Kelly GD. Influenza - a new problem? Med. J. Aust. 171(9), 504 (1999).
10. Lamb RA, Krug RM. Orthomyxoviruses. In: Fields Virology. Fields BN, Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA, 1487-1531 (2001).
11. Moriuchi H, Katsushima N, Nishimura H, Nakamura K, Numazaki Y. Community-acquired influenza C virus infection in children. J. Pediatr. 118(2), 235-238 (1991).
12. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004).
13. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
14. Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18(28), 3214-3222 (2000).
15. Chen Z, Matsuo K, Asanuma H et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutininand neuraminidase-expressing DNAs. Vaccine 17(7-8), 653-659 (1999).
16. Chen Z, Sahashi Y, Matsuo K et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16(16), 1544-1549 (1998).
17. Chen Z, Yoshikawa T, Kadowaki S et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80(Pt 10), 2559-2564 (1999).
18. Donnelly JJ, Friedman A, Martinez D et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1(6), 583-587 (1995). •• Compares the abilities of influenza DNA, inactivated virus and subvirion vaccines to elicit antibodies against human strains of virus in nonhuman primates and ferrets. DNA vaccines were shown to better protect ferrets against challenge with an antigenically distinct epidemic human influenza virus, suggesting that DNA vaccines may be more effective than contemporary clinically licensed vaccines against different strains of virus.
19. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15(8), 865-868 (1997).
20. Kodihalli S, Haynes JR, Robinson HL, Webster RG. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J. Virol. 71(5), 3391-3396 (1997). •• Showed that particle-mediated epidermal delivery (PMED) influenza DNA vaccines induce better protection against homologous viruses than the conventional killed vaccine.
21. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18(23), 2592-2599 (2000).
22. Lunn DP, Soboll G, Schram BR et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 17(18), 2245-2258 (1999).
23. Macklin MD, McCabe D, McGregor MW et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J. Virol. 72(2), 1491-1496 (1998). •• Showed that immunization of swine with a PMED influenza DNA vaccine induces superior protection against infection when compared with a licensed killed vaccine.
24. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J. Infect. Dis. 176(Suppl. 1), S50-S55 (1997).
25. Webster RG, Fynan EF, Santoro JC, Robinson H. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 12(16), 1495-1498 (1994).
26. Chen Z, Kadowaki S, Hagiwara Y et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 19(11-12), 1446-1455 (2001).
27. Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J. Virol. 69(12), 7712-7717 (1995).
28. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1(2), 127-131 (2000). • Shows that the improved protection afforded by PMED influenza DNA vaccines may be due, in part, to the de novo production of correctly folded hemagglutinin (HA) in vivo resulting in higher avidity antibody.
29. Laddy DJ, Yan J, Khan AS et al. Electroporation of synthetic DNA antigens offers protection in non-human primates challenged with highly pathogenic avian influenza. J. Virol. 83(9), 4624-4630 (2009).
30. Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3(6), e2517 (2008).
31. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181(3), 1133-1137 (2000).
32. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 12(1), 48-54 (2006).
33. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333-6339 (2006).
34. + T cells in protective immunity to influenza. Immunol. Rev. 211, 8-22 (2006).
35. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177(5), 2888-2898 (2006).
36. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
37. + T cells can promote survival and recovery after challenge. Int. Immunol. 12(1), 91-101 (2000).
38. + T-cell responses to conserved epitopes that are able to promote survival and recovery against lethal viral challenges in mice.
39. Fu TM, Guan L, Friedman A et al. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J. Immunol. 162(7), 4163-4170 (1999).
40. Okuda K, Ihata A, Watabe S et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19(27), 3681-3691 (2001).
41. Watabe S, Xin KQ, Ihata A et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19(31), 4434-4444 (2001).
42. + T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72(7), 5648-5653 (1998).
43. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl Acad. Sci. USA 87(24), 9568-9572 (1990).
44. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2(10), 1122-1128 (1996).
45. Eisenbraun MD, Fuller DH, Haynes JR. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12(9), 791-797 (1993).
46. Falo LD Jr. Targeting the skin for genetic immunization. Proc. Assoc. Am. Physicians 111(3), 211-219 (1999).
47. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40(1), 86-97 (2006).
48. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 373-388 (2003).
49. Haynes JR. Particle-mediated DNA vaccine delivery to the skin. Expert Opin. Biol. Ther. 4(6), 889-900 (2004).
50. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT. Particle-mediated nucleic acid immunization. J. Biotechnol. 44(1-3), 37-42 (1996).
51. Payne LG, Fuller DH, Haynes JR. Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Curr. Opin. Mol. Ther. 4(5), 459-466 (2002).
52. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27(18), 2506-2512 (2009). •• This PMED influenza DNA vaccine clinical trial was administered using a disposable clinical device and is the first to show that DNA vaccines can protect against influenza infection in humans.
53. Gnjatic S, Altorki NK, Tang DN et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 15(6), 2130-2139 (2009).
54. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol Rev. 14(2), 430-445 (2001).
55. Kantele A, Hakkinen M, Moldoveanu Z et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66(12), 5630-5635 (1998).
56. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113(7), 998-1007 (2004).
57. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18(24), 2753-2767 (2000).
58. Fuller DH, Rajakumar PA, Wilson LA et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76(7), 3309-3317 (2002). • Shows that PMED DNA immunization to the skin induces mucosal responses and affords protection against a mucosal challenge in nonhuman primates.
59. Fynan EF, Robinson HL, Webster RG. Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine. DNA Cell. Biol. 12(9), 785-789 (1993).
60. Huber VC, Thomas PG, McCullers JA. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27(8), 1192-1200 (2009).
61. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA, 90(24), 11478-11482 (1993). •• First study to demonstrate that influenza DNA immunization by PMED was superior for both the induction of antibody and for conferring protection compared with immunization with larger doses of DNA via intraperitoneal, intradermal or intramuscular needle injection.
62. Sharpe M, Lynch D, Topham S, Major D, Wood J, Loudon P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25(34), 6392-6398 (2007). • Shows that a PMED influenza DNA vaccine affords protection against highly pathogenic avian influenza in mice. Addition of a mucosal genetic adjuvant enhanced immunogenicity and prevented dissemination of detectable viremia in the blood after respiratory infection, possibly via the induction of enhanced mucosal immune responses.
63. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 73(3), 2094-2098 (1999).
64. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26(17), 2100-2110 (2008).
65. + cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254(1), 50-60 (1999).
66. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173(3), 1978-1986 (2004).
67. Justewicz DM, Webster RG. Long-term maintenance of B cell immunity to influenza virus hemagglutinin in mice following DNA-based immunization. Virology 224(1), 10-17 (1996).
68. Cerwenka A, Morgan TM, Dutton RW. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J. Immunol. 163(10), 5535-5543 (1999).
69. + T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166(3), 1813-1822 (2001).
70. + T cells that persist in the lungs. J. Exp. Med. 193(8), 981-986 (2001).
71. + T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167(6), 3293-3299 (2001).
72. Woodland DL. Cell-mediated immunity to respiratory virus infections. Curr. Opin. Immunol. 15(4), 430-435 (2003).
73. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102), 1745-1749 (1993). • This classical study established that vaccination with plasmid DNA encoding influenza A nucleoprotein results in the generation of nucleoprotein-specific cytotoxic T lymphocytes (CTLs) capable of providing protection against subsequent challenge with a heterologous strain of virus.
74. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
75. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000). •• This DNA vaccine clinical trial is the first study to demonstrate that a DNA vaccine can induce significant responses in humans. The PMED hepatitis B DNA vaccine used in this study induced protective levels of antibody and significant CTL responses in 100% of vaccinated subjects.
76. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24(21), 4475-4481 (2005). •• First clinical study to demonstrate that a PMED influenza DNA vaccine encoding the influenza HA gene is able to safely and effectively elicit serum hemagglutinationinhibition antibody responses in humans.
77. Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S. Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine 23(40), 4867-4878 (2005).
78. Talaat AM, Lyons R, Johnston SA. A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses. Vaccine 20(3-4), 538-544 (2001).
79. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21(31), 4604-4608 (2003).
80. Cassaday RD, Sondel PM, King DM et al. A Phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin. Cancer Res. 13(2 Pt 1), 540-549 (2007).
81. Houghton CS, Engelhorn ME, Liu C et al. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 25(29), 5330-5342 (2007).
82. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27(18), 2506-2512 (2009).
83. Arrington J, Braun RP, Dong L et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76(9), 4536-4546 (2002). • Demonstrates that bacterial toxin-based genetic adjuvants are a safe and effective strategy to enhance the potency of PMED DNA vaccination.
84. Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 24(23), 5016-5026 (2006).
85. Barouch DH. Rational design of gene-based vaccines. J. Pathol. 208(2), 283-289 (2006).
86. Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J. Virol. Methods 154(1-2), 121-127 (2008).
87. Barouch DH, Yang ZY, Kong WP et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79(14), 8828-8834 (2005).
88. Baird M, Wilson R, Young L et al. Bystander help within a polyepitope DNA vaccine improves immune responses to influenza antigens. Scand. J. Immunol. 60(4), 363-371 (2004).
89. Fuller DH, Shipley T, Allen TM et al. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 364(2), 245-255 (2007).
90. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266(2), 329-339 (2000).
91. Whitton JL, Sheng N, Oldstone MB, McKee TA. A 'string-of-beads' vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 67(1), 348-352 (1993). • The three studies listed above demonstrate that DNA vaccines can be formulated to elicit immune responses against multiple pathogenic antigens or epitopes. These studies show that competition between multiple encoded epitopes or antigens in a DNA vaccine can be overcome by separating the genes on separate vectors.
92. + T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80(24), 11991-11997 (2006).
93. Fuller DH, Rajakumar PA, Wu MS et al. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348(1), 200-215 (2006).
94. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J. Immunol. 180(10), 7019-7027 (2008).
95. Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112(1), 109-117 (2003).
96. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. 7(3), 168-173 (2000).
97. Larsen DL, Dybdahl-Sissoko N, McGregor MW et al. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. J. Virol. 72(2), 1704-1708 (1998).
98. Olsen CW. DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza. Vet. Microbiol. 74(1-2), 149-164 (2000).
99. Williman J, Lockhart E, Slobbe L, Buchan G, Baird M. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine 24(21), 4471-4474 (2006).
100. Daynes RA, Enioutina EY, Butler S, Mu HH, McGee ZA, Araneo BA. Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect. Immun. 64(4), 1100-1109 (1996).
101. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161(7), 3211-3214 (1998).
102. Pawelec G, Larbi A. Immunity and ageing in man: Annual Review 2006/2007. Exp. Gerontol. 43(1), 34-38 (2008).
103. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46(7), 1078-1084 (2008).
104. Klinman DM, Conover J, Bloom ET, Weiss W. Immunogenicity and efficacy of a DNA vaccine in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 53(4), B281-B286 (1998).
105. Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A. Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21(9-10), 843-848 (2003).
106. Bender BS, Ulmer JB, DeWitt CM et al. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine 16(18), 1748-1755 (1998). • One of the few studies to evaluate the impact of biological aging on the immunogenicity and protective efficacy of DNA vaccination.
107. Radu DL, Antohi S, Bot A, Weksler ME, Bona C. Plasmid expressing the influenza HA gene protects old mice from lethal challenge with influenza virus. Viral Immunol. 12(3), 217-226 (1999).
108. Barry MA, Johnston SA. Biological features of genetic immunization. Vaccine 15(8), 788-791 (1997).
109. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357(19), 1903-1915 (2007).
110. Yu X, Tsibane T, McGraw PA et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455(7212), 532-536 (2008).
111. Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C Jr. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J. Lab. Clin. Med. 92(5), 822-828 (1978).
112. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154(2), 245-256 (1986).
113. Cook JM, Gualde N, Hessel L et al. Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol. 109(1), 89-96 (1987).
114. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24(8), 1159-1169 (2006).
115. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16(2), 308-318 (2003).
116. Frasca D, Landin AM, Riley RL, Blomberg BB. Mechanisms for decreased function of B cells in aged mice and humans. J. Immunol. 180(5), 2741-2746 (2008).
117. + T cells. Immunol. Rev. 205, 220-228 (2005).
118. Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common γ chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J. Exp. Med. 190(7), 1013-1024 (1999).
119. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J. Exp. Med. 200(12), 1613-1622 (2004).
120. Maletto BA, Ropolo AS, Liscovsky MV, Alignani DO, Glocker M, Pistoresi-Palencia MC. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice. Clin. Immunol. 117(3), 251-261 (2005).
121. Bender BS, Johnson MP, Small PA. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology 72(4), 514-519 (1991).
122. Li SP, Cai Z, Shi W, Brunmark A, Jackson M, Linton PJ. Early antigen-specific response by naive CD8 T cells is not altered with aging. J. Immunol. 168(12), 6120-6127 (2002).
123. Linton PJ, Li SP, Zhang Y, Bautista B, Huynh Q, Trinh T. Intrinsic versus environmental influences on T-cell responses in aging. Immunol. Rev. 205, 207-219 (2005).
124. + T lymphocytes during primary influenza infection. Mech. Ageing Dev. 123(8), 1167-1181 (2002).
125. Effros RB, Cai Z, Linton PJ. CD8 T cells and aging. Crit. Rev. Immunol. 23(1-2), 45-64 (2003).
126. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr. Opin. Immunol. 17(5), 468-475 (2005).
127. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 4(2), 123-132 (2004).
128. Ahmed M, Lanzer KG, Yager EJ, Adams PS, Johnson LL, Blackman MA. Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice. J. Immunol. 182(2), 784-792 (2009).
129. Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205(3), 711-723 (2008). • Suggests that the efficacy of vaccines carrying multiple T-cell epitopes might be compromised in the elderly due to age-related declines in the size and diversity of the naive T-cell repertoire.
130. Cunningham-Rundles S. The effect of aging on mucosal host defense. J. Nutr. Health Aging 8(1), 20-25 (2004).
131. Harrod T, Martin M, Russell MW. Long-term persistence and recall of immune responses in aged mice after mucosal immunization. Oral Microbiol. Immunol. 16(3), 170-177 (2001).
132. Fujihashi K, McGhee JR. Mucosal immunity and tolerance in the elderly. Mech. Ageing Dev. 125(12), 889-898 (2004).
133. Grewe M. Chronological ageing and photoageing of dendritic cells. Clin. Exp. Dermatol. 26(7), 608-612 (2001).
134. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357(9272), 1937-1943 (2001).
135. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001).
136. Huber VC, Kleimeyer LH, McCullers JA. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 26(42), 5381-5388 (2008).
137. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306(1), 181-195 (2003).
138. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22(13-14), 1799 - 1809 (2004).